.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,304,078

« Back to Dashboard
Patent 7,304,078 protects ZONTIVITY and is included in one NDA.

This patent has one hundred and forty-seven patent family members in thirty-four countries.

Summary for Patent: 7,304,078

Title:Thrombin receptor antagonists
Abstract: Heterocyclic-substituted tricyclics of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond; n is 0 2; Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14; R.sup.13 and R.sup.14 are independently selected from (C.sub.1 C.sub.6)alkyl, (C.sub.3 C.sub.8)cycloalkyl, --OH, (C.sub.1 C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1 C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3 6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
Inventor(s): Chackalamannil; Samuel (Califon, NJ), Greenlee; William J. (Teaneck, NJ), Wang; Yuguang (North Brunswick, NJ), Wu; Wenxue (Princeton Junction, NJ), Veltri; Enrico P. (Princeton, NJ), Xia; Yan (Edison, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/412,982
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 12th percentile
Forward Citations: 9th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Aralez Pharms
ZONTIVITY
vorapaxar sulfate
TABLET;ORAL204886-001May 8, 2014RXYes7,304,078► subscribeYY REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,304,078

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,713,999Thrombin receptor antagonists► subscribe
6,645,987 Nor-seco himbacine derivatives useful as thrombin receptor antagonists► subscribe
6,894,065 Thrombin receptor antagonists► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,304,078

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina028952► subscribe
Argentina039570► subscribe
Argentina045809► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc